Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.

Today it is happening again with GLP1 agonists like Semaglutide with ... have in any other physical or consultation in the past." A specialized health and weight loss program will be recommended.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...